We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer (BAYRY) to Report Q3 Earnings: What's in the Cards?
Read MoreHide Full Article
Bayer AG (BAYRY - Free Report) is scheduled to release third-quarter 2020 results on Nov 3.
The company has an excellent track record, delivering an earnings beat in three of the trailing four quarters by 17.75%, on average.
Shares of the company have decreased 35.9% in the year so far compared with the industry’s decline of 0.6%.
Let’s see how things are shaping up for the quarter to be reported.
Factors at Play
The Bayer Group’s businesses turned in a solid performance in the second quarter of 2020 despite the COVID-19 pandemic and the associated uncertainties
The Crop Science sector registered growth while sales at Pharmaceuticals and Consumer Health declined.
However, in September 2020, the company stated tha, due to the pandemic, the company’s Crop Science and Pharmaceuticals divisions generated lower revenues. We expect the trend to continue in the third quarter.
The Crop Sciencesector, is characterized by reduced growth expectations due to low commodity prices for major crops, intense competition in soy, and reduced biofuel consumption. This is compounded by negative currency effects, some of which are significant as in the case of the Brazilian Real. This situation is unlikely to improve considerably in the near-term.
The Consumer Health business has shown strong business in the third quarter and the trend is expected to continue.
In September 2020, the company stated that the COVID-19 pandemic led to headwinds in the 2020 fiscal year for Bayer, with significant currency effects presenting an additional burden on sales and earnings growth. The company therefore confirmed its adjusted outlook for 2020. For 2020, the company expects currency-adjusted growth in sales between €43 billion and €44 billion. Core earnings per share are expected between €6.70 and €6.90 on a currency-adjusted basis.
In October 2020, Bayer’s development partner, Janssen Research & Development, LLC, a subsidiary of Johnson and Johnson (JNJ - Free Report) a submitted a supplemental New Drug Application (sNDA) to the FDA for a new indication to expand the use of Xarelto (rivaroxaban) in people with peripheral artery disease (PAD) to include those after recent lower- extremity revascularization due to symptomatic PAD.The company is expected to provide updates on the same in the third quarter.
Moreover, investors will be keen to know if the coronavirus pandemic has affected the demand for other marketed drugs and those in clinical studies.
RECENT DEVELOPMENTS
In October 2020, the company acquired AsklepiosBioPharmaceutical, Inc. (AskBio), a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies across different therapeutic areas. Through the acquisition, Bayer will add an industry-leading adeno-associated virus (AAV)-based gene therapy platform to its portfolio, which has already demonstrated applicability across different therapeutic areas. It also includes a state-of-the-art gene therapy technology platform as well as existing gene therapy manufacturing platform. We expect the company to provide an update on this in the third quarter.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Bayer this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below.
Earnings ESP: Bayer has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year. These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Bayer (BAYRY) to Report Q3 Earnings: What's in the Cards?
Bayer AG (BAYRY - Free Report) is scheduled to release third-quarter 2020 results on Nov 3.
The company has an excellent track record, delivering an earnings beat in three of the trailing four quarters by 17.75%, on average.
Shares of the company have decreased 35.9% in the year so far compared with the industry’s decline of 0.6%.
Let’s see how things are shaping up for the quarter to be reported.
Factors at Play
The Bayer Group’s businesses turned in a solid performance in the second quarter of 2020 despite the COVID-19 pandemic and the associated uncertainties
The Crop Science sector registered growth while sales at Pharmaceuticals and Consumer Health declined.
However, in September 2020, the company stated tha, due to the pandemic, the company’s Crop Science and Pharmaceuticals divisions generated lower revenues. We expect the trend to continue in the third quarter.
The Crop Sciencesector, is characterized by reduced growth expectations due to low commodity prices for major crops, intense competition in soy, and reduced biofuel consumption. This is compounded by negative currency effects, some of which are significant as in the case of the Brazilian Real. This situation is unlikely to improve considerably in the near-term.
The Consumer Health business has shown strong business in the third quarter and the trend is expected to continue.
In September 2020, the company stated that the COVID-19 pandemic led to headwinds in the 2020 fiscal year for Bayer, with significant currency effects presenting an additional burden on sales and earnings growth. The company therefore confirmed its adjusted outlook for 2020. For 2020, the company expects currency-adjusted growth in sales between €43 billion and €44 billion. Core earnings per share are expected between €6.70 and €6.90 on a currency-adjusted basis.
In October 2020, Bayer’s development partner, Janssen Research & Development, LLC, a subsidiary of Johnson and Johnson (JNJ - Free Report) a submitted a supplemental New Drug Application (sNDA) to the FDA for a new indication to expand the use of Xarelto (rivaroxaban) in people with peripheral artery disease (PAD) to include those after recent lower- extremity revascularization due to symptomatic PAD.The company is expected to provide updates on the same in the third quarter.
Moreover, investors will be keen to know if the coronavirus pandemic has affected the demand for other marketed drugs and those in clinical studies.
RECENT DEVELOPMENTS
In October 2020, the company acquired AsklepiosBioPharmaceutical, Inc. (AskBio), a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies across different therapeutic areas. Through the acquisition, Bayer will add an industry-leading adeno-associated virus (AAV)-based gene therapy platform to its portfolio, which has already demonstrated applicability across different therapeutic areas. It also includes a state-of-the-art gene therapy technology platform as well as existing gene therapy manufacturing platform. We expect the company to provide an update on this in the third quarter.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Bayer this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below.
Earnings ESP: Bayer has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #4. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks That Warrant a Look
Here are some biotech stocks with the right mix of elements to beat on earnings this time around:
Alkermes Plc. (ALKS - Free Report) )has an Earnings ESP of +142.86% and a Zacks Rank #3.
Alnylam (ALNY - Free Report) has an Earnings ESP of +4.23% and a Zacks Rank #3.
Bayer Aktiengesellschaft Price and Consensus
Bayer Aktiengesellschaft price-consensus-chart | Bayer Aktiengesellschaft Quote
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year. These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>